Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 8:22 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 1,368 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dextrose Control Clear all
Completed Not applicable Interventional

Prebiotic in Preterm Infants

NCT03306316
View directory record Official record
Conditions
Preterm Infant, Development, Infant, Nutrition
Interventions
Prebiotic, Dextrose Control
Dietary Supplement
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
7 Days to 10 Days
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Nov 1, 2026, 8:22 AM EST
Completed Phase 2 Interventional Results available

Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic Patients

NCT02802228
View directory record Official record
Conditions
Portal Hypertension, Liver Cirrhosis
Interventions
Ifetroban, Placebo
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Tampa, Florida • Indianapolis, Indiana • Columbus, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Nov 1, 2026, 8:22 AM EST
Withdrawn Not applicable Interventional Accepts healthy volunteers

The Feasibility of Using a General Health Screen to Increase HIV Testing in Community Pharmacies

NCT01751100
View directory record Official record
Conditions
HIV Infections
Interventions
HIV Test Offer, General Health Screen Offer
Behavioral
Lead sponsor
North Bronx Healthcare Network
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 8, 2015 · Synced Nov 1, 2026, 8:22 AM EST
Completed No phase listed Observational

Anti-Inflammatory Effects of Time-Restricted Feeding

NCT04728165
View directory record Official record
Conditions
Psoriasis, Systemic Inflammation
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 80 Years · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Nov 1, 2026, 8:22 AM EST
Recruiting Phase 3 Interventional

Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer

NCT07473128
View directory record Official record
Conditions
Limited Stage Small Cell Lung Cancer
Interventions
Trilaciclib, Saline (0.9% NaCl)
Drug
Lead sponsor
Pharmacosmos A/S
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Nov 1, 2026, 8:22 AM EST
Recruiting Phase 3 Interventional

A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

NCT07668336
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Orforglipron, Dulaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
10 Years to 17 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
17
States / cities
Sacramento, California • San Diego, California • Stamford, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 1, 2026, 8:22 AM EST
Recruiting Not applicable Interventional

Pilot-Testing Real-Time Engagement for Learning to Effectively Control Type 2 Diabetes

NCT07270016
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hyperglycemia, Physical Inactivity, Lifestyle (Sedentary Behavior and Physical Activity), Continuous Glucose Monitoring
Interventions
Healthmine app
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
16 Years to 24 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Nov 1, 2026, 8:22 AM EST
Not yet recruiting Phase 2 Interventional

SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease

NCT03867487
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, NAFLD, Pediatric NAFLD
Interventions
Empagliflozin 10 MG, Placebo Oral Tablet
Drug
Lead sponsor
Justin Ryder
Other
Eligibility
12 Years to 20 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Nov 1, 2026, 8:22 AM EST
Completed Not applicable Interventional Results available

Scripps Wired for Health Monitoring Study

NCT01975428
View directory record Official record
Conditions
Diabetes, Hypertension, Cardiac Arrhythmia
Interventions
DM Pgm + device, Control
Device · Behavioral
Lead sponsor
Scripps Translational Science Institute
Other
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2023 · Synced Nov 1, 2026, 8:22 AM EST
Active, not recruiting Not applicable Interventional

Texting for Diabetes

NCT03025984
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Texting
Behavioral
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Nov 1, 2026, 8:22 AM EST
Completed Not applicable Interventional Results available

Study Of Drinks With Artificial Sweeteners in People With Type 2 Diabetes

NCT03944616
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Diet Beverage, Water
Behavioral
Lead sponsor
University of California, Irvine
Other
Eligibility
35 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Irvine, California • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Nov 1, 2026, 8:22 AM EST
Recruiting Phase 2 Interventional Accepts healthy volunteers

Regulation of Endogenous Glucose Production by Central KATP Channels

NCT03540758
View directory record Official record
Conditions
Diabetes Mellitus, Glucose Metabolism Disorders
Interventions
Diazoxide, Nicotinic acid, Placebo
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
21 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Nov 1, 2026, 8:22 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Real-time Adaptation to Changes in Insulin Sensitivity

NCT01261052
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
The Fading Memory Proportional Derivative/Adaptive Proportional Derivative Algorithm, The Adaptive Proportional Derivative Algorithm
Device
Lead sponsor
Legacy Health System
Other
Eligibility
21 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Nov 1, 2026, 8:22 AM EST
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder)When an Optimal Dose is Taken With Varied Carbohydrate Intake

NCT00747006
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions
TI Inhalation Powder and Humalog (Amendment 1), TI Inhalation Powder (original protocol)
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Nov 1, 2026, 8:22 AM EST
Completed Not applicable Interventional Results available

Study to Find Out if Intensive Diabetes Clinic and Continuous Glucose Monitors Help Teenagers With Diabetes

NCT01083433
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Diabetes related psychological counseling and education, Continuous Glucose Monitor
Behavioral · Device
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
10 Years to 18 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Nov 1, 2026, 8:22 AM EST
Withdrawn Not applicable Interventional

Inpatient Closed Loop Glucose Control With the Gen 2 GlucoSTAT

NCT04227626
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes Treated With Insulin
Interventions
GlucoSTAT
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Nov 1, 2026, 8:22 AM EST
Completed Phase 1Phase 2 Interventional

IVIG - West Nile Encephalitis: Safety and Efficacy

NCT00068055
View directory record Official record
Conditions
West Nile Virus
Interventions
Omr-lgG-am, Polygam® S/D, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
66
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2011 · Synced Nov 1, 2026, 8:22 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

The Impact of Low Glycemic Index Nutritional Shake on Glucose Regulation in Overweight and Obese Adults

NCT06856460
View directory record Official record
Conditions
Hyperglycemia, Obesity Prevention
Interventions
powder shake with very low glycemic index, Ceral Breakfast
Dietary Supplement
Lead sponsor
Arizona State University
Other
Eligibility
25 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Nov 1, 2026, 8:22 AM EST
Completed Not applicable Interventional

Technological Advances in Glucose Management in Older Adults

NCT03078491
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Older Adults, Hypoglycemia
Interventions
eCGM (enhanced CGM)
Other
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
65 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Nov 1, 2026, 8:22 AM EST
Completed No phase listed Observational

Impact of Antenatal Betamethasone on Plasma Glucose Levels

NCT00585676
View directory record Official record
Conditions
Hyperglycemia
Interventions
Not listed
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Nov 1, 2026, 8:22 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Financial Incentives and Text Messaging to Improve African American Womens' Glycemic Control

NCT02384265
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
IM/SMS + Incentive Condition
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
25 Years to 65 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Nov 1, 2026, 8:22 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of CR6261, a Monoclonal Antibody Against the Influenza A Virus

NCT01406418
View directory record Official record
Conditions
Influenza
Interventions
CR6261 2 mg/kg, CR6261 5 mg/kg, CR6261 15 mg/kg, CR6261 30 mg/kg, CR6261 50 mg/kg, Placebo
Biological
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Nov 1, 2026, 8:22 AM EST
Completed Phase 3 Interventional Results available

A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin

NCT04537923
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Tirzepatide, Insulin Lispro (U100)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
40
States / cities
Sheffield, Alabama • Fresno, California • Huntington Park, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Nov 1, 2026, 8:22 AM EST
Active, not recruiting Not applicable Interventional

Diabetes Toolkit at Discharge

NCT05663931
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Insulin Dependent Diabetes
Interventions
DM Discharge Toolkit
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 90 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 1, 2026, 8:22 AM EST